secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001434647-26-000029
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Q1 2026 net revenue $36.2M (+78% YoY); net income $37.9M; cash $236.8M after debt repayment
--------------------------------------------------------------------------------

- MIPLYFFA net revenue $24.6M; total net revenue $36.2M vs $20.4M in Q1 2025.
- Completed $50M sale of SDX portfolio to Commave Therapeutics; prepaid $63.1M term loan, now debt-free.
- Net income of $37.9M ($0.60 diluted) includes $43.3M one-time gain; adjusted net income $11.5M ($0.18 diluted).
- Cash, equivalents and securities $236.8M as of March 31, 2026; no near-term capital market dependency.
- Enrolled 62 patients in Phase 3 DiSCOVER trial for Vascular Ehlers-Danlos Syndrome; FDA meeting expected H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143464726000029/0001434647-26-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143464726000029/zvra-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001434647-26-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer